SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Tularik Inc. (TLRK)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: mopgcw who wrote (560)2/2/2004 10:15:44 PM
From: scaram(o)uche  Read Replies (1) of 598
 
this is about what we've been told.....

"With over 260 patients dosed to date, T67 has shown objective partial responses (greater than 50% reduction in tumor size) in patients with HCC and an acceptable toxicity profile."

driving me nuts. I very much respect the job that Goeddel is doing, but have never seen justification for taking T67 forward. Same thing that I was saying back when Wilder (Nigel?) made that great "can't afford to be out of the stock" call.

But, guess what? Goeddel knows more about the project than me.

:-)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News